Clinical Trial: A Pilot Study of the Efficacy of Recombinant Alpha Interferon (IFN-A2b) and zidovudine (AZT) in the Treatment of Progressive Multifocal Leukoencephalopathy (PML) Complicating HIV-1 Infection

This study has been completed.

Sponsored by: University of Miami
Information provided by: AIDS Clinical Trials Information Service

Purpose

To study the effectiveness of alpha interferon (IFN-A2b) and zidovudine (AZT) in treating progressive multifocal leukoencephalopathy (PML) as a complication of HIV-1 infection.

Condition Treatment or Intervention
HIV Infections
Leukoencephalopathy, Progressive Multifocal
 Drug: Interferon alfa-2b
 Drug: Zidovudine

MedlinePlus related topics:  AIDS;   Encephalitis;   Neurologic Diseases;   Viral Infections

Study Type: Interventional
Study Design: Treatment, Dose Comparison

Eligibility

Ages Eligible for Study:  18 Years   -   65 Years,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria

Patients must have:

  • HIV seropositivity by both ELISA and Western blot.
  • Biopsy proven progressive multifocal leukoencephalopathy (PML).

Exclusion Criteria

Co-existing Condition: Patients with the following conditions or symptoms are excluded:

Patients with the following are excluded:

Prior Medication: Excluded:

  • Patients receiving interferon for other reasons.

Location Information


Florida
      Univ of Miami School of Medicine, Miami,  Florida,  33136,  United States

More Information

Study ID Numbers:  074A
Record last reviewed:  March 1991
Last Updated:  October 13, 2004
Record first received:  November 2, 1999
ClinicalTrials.gov Identifier:  NCT00002270
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08


Source: ClinicalTrials.gov
Cache Date: April 9, 2005

Resources